CE-Ventures, the corporate venture capital arm of Crescent Enterprises, is investing in Aptadir Therapeutics, an Italy-based biotech that has closed a USD 45.4 million (EUR 40 million) seed round. The deal marks the UAE investor's entry into RNA-based genetic disorder treatment, a field with implications for how the region's capital connects to global life-sciences research.
For Dubai and UAE readers tracking where local venture capital is flowing, this is a case of a homegrown fund backing frontier biotech rather than the more familiar fintech or logistics startups. CE-Ventures operates as Crescent Enterprises' corporate venture arm, and its participation in Aptadir's seed round signals appetite for early-stage, science-heavy bets outside the region.
What the funding will do
Aptadir says the seed capital will go toward advancing its RNA-based treatments for genetic disorders, with a lead program targeting Fragile X Syndrome. The company remains at the preclinical stage and plans to use the funds to push its investigational therapies toward clinical testing.
The science centers on RNA inhibitors the company calls DNMTs Interacting RNAs, or DiRs. These molecules are designed to interfere with abnormal DNA methylation, a process implicated in a range of genetic conditions. Aptadir's lead candidate, CAP1-FMR1, is built to target Fragile X Syndrome by attempting to reactivate the FMR1 gene, which is silenced in patients with the condition.
The research behind the platform
The science underpinning Aptadir's platform draws on work from several institutions: Beth Israel Deaconess Medical Center, the Italian National Research Council, the Cancer Science Institute of Singapore, and City of Hope National Medical Center. That multi-institution foundation spans genetics research hubs in the United States, Europe, and Asia, reflecting the kind of cross-border scientific collaboration increasingly common in early-stage biotech.
Beyond its lead Fragile X program, Aptadir intends to apply its DiR platform to additional genetic disorders as well as oncology programs, suggesting the company sees its core technology as adaptable to multiple disease areas rather than limited to a single indication.
Why this matters for UAE investors
CE-Ventures' involvement places a UAE-based corporate venture fund inside a specialized therapeutic-development story still years from clinical validation, given Aptadir's preclinical status. For Crescent Enterprises, the investment extends its venture portfolio into biotech, a sector that requires patient capital and carries the long development timelines typical of drug discovery.
The seed round itself, at USD 45.4 million, is a sizable raise for a company still in preclinical development, underscoring investor confidence in the DiR platform's potential applications across genetic disorders and oncology. What happens next will depend on Aptadir's ability to move CAP1-FMR1 and any future candidates from the lab toward human trials.
